癌症免疫中CD70,CD80和TIGIT的Epitranscriptomics调节
Christos Panagiotis Rigopoulos1,2, Marios Gkoris1,2, Ilias Georgakopoulos-Soares3
1Department of Life Sciences, School of Sciences, European University Cyprus, 1516 Nicosia, Cyprus.
International journal of molecular sciences
|June 26, 2025
概括
这项研究揭示了RNA修饰 (m1A,m5C,m6A) 如何调节癌症中的关键免疫检查点基因. 使用RNA修饰酶的新预后特征可以预测患者的生存率并改善癌症治疗策略.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 瘤发生包括细胞变化,如持续生长和免疫逃避.
- 表观遗传改变,包括RNA修饰 (m1A,m5C,m6A),都与癌症的发展有关.
- 免疫调节剂 (CD70,CD80,TIGIT) 对于T细胞激活和瘤免疫逃避至关重要.
研究的目的:
- 研究RNA修饰在调节各种癌症免疫检查点基因 (CD70,CD80,TIGIT) 的作用.
- 探索表皮转录学数据作为癌症预后生物标志物的潜力.
- 开发基于RNA修饰酶的预后特征,用于患者风险分层.
主要方法:
- 在泛癌研究中分析表观转录学数据.
- 功能性丰富分析以了解生物途径.
- 生存建模以评估预后价值.
- 构建一个四基因预后特征 (YTHDF3,RBM15B,IGF2BP2,TRMT61A).
主要成果:
- 在多个固体瘤中,m6A,m5C和m1A修改极大地调节了CD70,CD80和TIGIT的表达.
- 确定RNA修饰酶是潜在的预后生物标志物.
- 开发的四基因特征准确地将患者分为不同的风险组,在八种癌症类型中具有不同的整体生存结果.
结论:
- RNA修饰配置文件显著影响免疫检查点基因表达,并可以作为有价值的预后指标.
- 这项研究提供了关于表皮转录组对免疫检查点的机制调节的见解.
- 体转录体标记物对个性化瘤学和增强免疫治疗策略的翻译有希望.
关键词:
CD7070 CD7070 CD7070 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70 CD70CD8080 CD8080 CD8080 CD8080 CD8080 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80基因组RNA的修改 基因组RNA的改变这是一个紧张的紧张.m1A1A 在线观看m5C 在线观看m6A 一个很好的.进行多主题分析.胰腺癌是一种癌症.相关概念视频
Receptor Downregulation in MVBs
2.2K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.2K
T Cell Activation and Clonal Selection
5.8K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
5.8K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Tumor Immunotherapy
675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675


